Columnistas Expertos

Tamila L. Kindwall-Keller
Columnista Experta de SIIC

Medical Oncology Fellow, Division of Hematology/Oncology. Arthur G. James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, EE.UU., Columbus, EE.UU.

Artículos publicados (selección):

ELINAFIDA, ESTADO ACTUAL DE UNA NAFTALIMIDA ACTIVA
Columnista Experta de SIIC Tamila L. Kindwall-Keller en colaboración con Miguel A. Villalona-Calero , Medical Oncologist, Associate Professor of Medicine. Division of Hematology/Oncology. Arthur G. James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University

Primera edición en siicsalud: 8 de abril, 2003
Sección Artículos originales, subsección Expertos de Iberoamérica,
página /des/expertocompleto.php/20110
Especialidad principal: Farmacología

Especialidades relacionadas:

Medicina Interna,

Oncología,

Hypermethylation induced decrease in Sp1/Sp3 binding is associated with reduced p21Cip1 expression in response to depsipeptide treatment, Molecular and Cellular Biology. (Accepted Pending Revisions) :

Lung specific expression of mutant p53 (273H) results in high frequency of lung adenocarcinoma in transgenic mice, Oncogene (In Press) :

Mitomycin C as a Modulator of Irinotecan Anticancer Activity, Oncology 16(16):21-25, 2002

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies, Clinical Cancer Research 8:2142-2148, 2002

Pharmaco-biologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies, Journal of Clinical Oncology 20:2616-2623, 2002

A pilot trial of G3139, a bcl-2 antisense oligonucleotide, with paclitaxel in patients with chemorefractory small cell lung cancer, Annals of Oncology 13:539-45, 2002

Detection of transgene and host endogenous homologous gene expression and silencing using RT-PCR-Heteroduplex technique in transgenic animal models, Biotechniques 33:58-66, 2002

A Phase I And Pharmacokinetic Study of ET-743, a Novel DNA Minor Groove Binder of Marine Origin Administered as a 1-hour infusion daily x 5 Days, Clinical Cancer Research 8:75-85, 2002

Tamila L. Kindwall-Keller

ua40317

Acerca de SIIC

Acceso para suscriptores